United Arab Emirates has approved use for Vaccine.
Sinopharm also began testing a second inactivated virus vaccine, this one developed by the Beijing Institute of Biological Products. After running early clinical trials in China, they launched Phase 3 trials in the United Arab Emirates and Argentina. Over the summer, the company later said, the government gave it approval to inject hundreds of thousands of people with its two experimental vaccines. On Sept. 14, the U.A.E. gave emergency approval for Sinopharm’s vaccine to use on health care workers before Sinopharm shared data indicating it was safe and effective. In October, the chairman of Sinopharm said the company was gearing up manufacturing for their two vaccines, with plans for producing a billion doses a year.
To remove first post, remove entire topic.
United Arab Emirates has approved use for Vaccine.
Sinopharm also began testing a second inactivated virus vaccine, this one developed by the Beijing Institute of Biological Products. After running early clinical trials in China, they launched Phase 3 trials in the United Arab Emirates and Argentina. Over the summer, the company later said, the government gave it approval to inject hundreds of thousands of people with its two experimental vaccines. On Sept. 14, the U.A.E. gave emergency approval for Sinopharm’s vaccine to use on health care workers before Sinopharm shared data indicating it was safe and effective. In October, the chairman of Sinopharm said the company was gearing up manufacturing for their two vaccines, with plans for producing a billion doses a year.
The Wuhan Institute of Biological Products developed an inactivated virus vaccine, which the state-owned Chinese company Sinopharm put into clinical tests. The Phase 1/2 trial showed that the vaccine produced antibodies in volunteers, some of whom experienced fevers and other side effects. They launched Phase 3 trials in the United Arab Emirates in July, and in Peru and Morocco the following month. Over the summer, the company later said, the government gave it approval to inject hundreds of thousands of people with its two experimental vaccines. On Sept. 14, the U.A.E. gave emergency approval for Sinopharm’s vaccine to use on health care workers. Updated Sept. 15
The Wuhan Institute of Biological Products developed an inactivated virus vaccine, which the state-owned Chinese company Sinopharm put into clinical tests. The Phase 1/2 trial showed that the vaccine produced antibodies in volunteers, some of whom experienced fevers and other side effects. They launched Phase 3 trials in the United Arab Emirates in July, and in Peru and Morocco the following month. Over the summer, the company later said, the government gave it approval to inject hundreds of thousands of people with its two experimental vaccines. On Sept. 14, the U.A.E. gave emergency approval for Sinopharm’s vaccine to use on health care workers. Updated Sept. 15
Riham Muqattash, Ibrahim Niankara, and Rachidatou I. Traoret
interdisciplinary research on the potential effects of the coronavirus pandemic , this article presents a novel data set on individuals’ COVID-19 vaccine preferences in the United Arab Emirates (UAE). The menu of our stated preference survey questionnaire is framed based on the World Health Organization's (WHO) SAGE working group on immunization developed matrix of vaccine determinants , which was itself informed by a systematic review of peer reviewed and grey literature, and by the expertise of the working group. Our survey was designed in a bilingual (Arabic and English) format, using Google Forms platform and delivered to respondents aged 18 years and older using the snowball sampling method between July 4th and August 4th 2020, gathering a total of 1109 responses. Study participants were recruited across all seven emirates of the UAE (see figure 1). As presented in the conceptual framework (see figure 2), the data set comprises (i) respondents socio-economic and demographic information, (ii) respondents willingness to spend time, and money to get the Covid-19 vaccine, and (iii) the vaccine determinants identified by the WHO's SAGE working group on immunization.
Source .
Riham Muqattash, Ibrahim Niankara, and Rachidatou I. Traoret
interdisciplinary research on the potential effects of the coronavirus pandemic , this article presents a novel data set on individuals’ COVID-19 vaccine preferences in the United Arab Emirates (UAE). The menu of our stated preference survey questionnaire is framed based on the World Health Organization's (WHO) SAGE working group on immunization developed matrix of vaccine determinants , which was itself informed by a systematic review of peer reviewed and grey literature, and by the expertise of the working group. Our survey was designed in a bilingual (Arabic and English) format, using Google Forms platform and delivered to respondents aged 18 years and older using the snowball sampling method between July 4th and August 4th 2020, gathering a total of 1109 responses. Study participants were recruited across all seven emirates of the UAE (see figure 1). As presented in the conceptual framework (see figure 2), the data set comprises (i) respondents socio-economic and demographic information, (ii) respondents willingness to spend time, and money to get the Covid-19 vaccine, and (iii) the vaccine determinants identified by the WHO's SAGE working group on immunization.
The recent emergence and global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, widely referred to as “COVID-19”, has posed significant threats to public health systems, and exacerbated national economic conditions worldwide []. Despite its significance for designing an effective vaccination program against the COVID-19 pandemic, to date no data manuscript addresses nor provides data for analyzing COVID-19 vaccine hesitancy (or preference more broadly) within a health/economic system.
On March 2012 however, the WHO's SAGE group on immunization developed a matrix of vaccine demand determinants, categorized into contextual, individual & group, and vaccine-specific . The menu of survey questions used to collect our currently shared COVID-19 vaccine preference data is framed based on this matrix. The link to our online survey questionnaire, along with a PDF copy of the actual questionnaire, and the csv format of the analyzed responses to the questionnaire are all provided as supplementary files to this manuscript. Although applied to COVID-19 vaccine preference analysis in the UAE, our presented data framework [see figure (2)] is general combining three key research paradigms in the scientific literature: the technology acceptance model (TAM), the framework on vaccine skepticism, and random utility theory.
Figure (1) below shows the geographical map along with the frequency count, and relative percent frequency count of respondents across the seven emirates of the UAE. It can be noted that our data contains 1109 respondents, 796 (71.78%) of which are from Abu Dhabi, 129 (11.63%) from Dubai, 80 (7.21%) from Sharjah, 13 (1.17%) from Ras Al Khaimah, 50 (4.51%) from Ajman, 34 (3.07%) from Fujairah, and finally 7 (0.63%) from Umm al Quwain.
The recent emergence and global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, widely referred to as “COVID-19”, has posed significant threats to public health systems, and exacerbated national economic conditions worldwide []. Despite its significance for designing an effective vaccination program against the COVID-19 pandemic, to date no data manuscript addresses nor provides data for analyzing COVID-19 vaccine hesitancy (or preference more broadly) within a health/economic system.
On March 2012 however, the WHO's SAGE group on immunization developed a matrix of vaccine demand determinants, categorized into contextual, individual & group, and vaccine-specific . The menu of survey questions used to collect our currently shared COVID-19 vaccine preference data is framed based on this matrix. The link to our online survey questionnaire, along with a PDF copy of the actual questionnaire, and the csv format of the analyzed responses to the questionnaire are all provided as supplementary files to this manuscript. Although applied to COVID-19 vaccine preference analysis in the UAE, our presented data framework [see figure (2)] is general combining three key research paradigms in the scientific literature: the technology acceptance model (TAM), the framework on vaccine skepticism, and random utility theory.
Figure (1) below shows the geographical map along with the frequency count, and relative percent frequency count of respondents across the seven emirates of the UAE. It can be noted that our data contains 1109 respondents, 796 (71.78%) of which are from Abu Dhabi, 129 (11.63%) from Dubai, 80 (7.21%) from Sharjah, 13 (1.17%) from Ras Al Khaimah, 50 (4.51%) from Ajman, 34 (3.07%) from Fujairah, and finally 7 (0.63%) from Umm al Quwain.
In this representation however, given that the stated time each individual is willing to spend (indirect cost), and the amount of money the individual is willing to spend to get the vaccine (direct cost) are both under the control of the individual decision maker, they are necessarily endogenous determinants of the vaccine decision outcome. This implicitly means bidirectional relationships would prevail between these two determinants on the one hand, and the vaccine decision outcome on the other hand. Such bidirectional relationships (endogeneity) would have to be taken into account in any statistical modeling of the vaccine decision outcome.
The data collected based on this conceptual framework, through the online questionnaire include the socio-economic and demographic characteristics of the participants (see table 1 below); the personal and peer influences on individual perceived COVID-19 vaccine utility (see table 2 below); the contextual influences on individual perceived COVID-19 vaccine utility (see table 3 below); the vaccine specific influences on individual perceived COVID-19 vaccine utility (see table 4 below); and finally the vaccine decision outcome variable, along with the two endogenous vaccine decision determinants (see table 5 below).
In this representation however, given that the stated time each individual is willing to spend (indirect cost), and the amount of money the individual is willing to spend to get the vaccine (direct cost) are both under the control of the individual decision maker, they are necessarily endogenous determinants of the vaccine decision outcome. This implicitly means bidirectional relationships would prevail between these two determinants on the one hand, and the vaccine decision outcome on the other hand. Such bidirectional relationships (endogeneity) would have to be taken into account in any statistical modeling of the vaccine decision outcome.
The data collected based on this conceptual framework, through the online questionnaire include the socio-economic and demographic characteristics of the participants (see table 1 below); the personal and peer influences on individual perceived COVID-19 vaccine utility (see table 2 below); the contextual influences on individual perceived COVID-19 vaccine utility (see table 3 below); the vaccine specific influences on individual perceived COVID-19 vaccine utility (see table 4 below); and finally the vaccine decision outcome variable, along with the two endogenous vaccine decision determinants (see table 5 below).
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Published by Elsevier Inc.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Hot Forum Topics
